Posts Tagged: start-up companies
Phase 2 clinical trial targeting diabetes
TIAP portfolio company Zucara Therapeutics moves their lead program targeting diabetes into Phase II clinical trials. Read more here.
Why this news is important:
Zucara has achieved the development milestones required to secure the remaining funds available from its previously announcedUS$21 million Series A Financing.
Zucara plans to file an investigational new drug (“IND”) application for a Phase 2 trial by year end, with initiation of first patient dosing expected in Q1 2023.
ZT-01 has the potential to become the first therapeutic designed ...
Read more
Highly Positive Results from PoC Phase 1b trial of ZT-01 – Type 1 Diabetes
Zucara Therapeutics announced highly positive results from its proof-of-concept Phase 1b trial of ZT-01 in people with Type 1 diabetes (“T1D”). Please see the press release here. Why this news is important:
This trial confirms ZT-01’s mechanism of action in restoring glucagon release in patients with T1D.
First-in-class ZT-01, meaningfully restored glucagon release in nearly 90% of treated patients compared to placebo (p<0.0001). This therapy has the potential to become the first therapeutic to prevent hypoglycemia in people with insulin-dependent diabetes.
Positive results from this trial will enable Zucara to further evaluate ZT-01 in a multi-center Phase 2 ...
Read more
Phenotips Raises $2.5M in First Round of Financing
Our startup company, Phenotips (formerly Gene42), announced in September, 2021, that it raised C$2.5M in its first round of financing. TIAP was an early investor and most recently, in this round, participated with additional $100K through its FedDev program. This brings TIAP's total investment as of September 2021 to $300K. Read more about the financing round here.
Phenotips has developed the world’s first "Genomic Health Record,” which offers software to standardize and share genomic medicine workflows. It is now translated into 5 ...
Read more
Funding for Zucara Therapeutics Expansion Into ZT-01 Development Program to Type 2 Diabetes
November 2, 2020: Zucara Therapeutics Inc., a diabetes life sciences startup funded by TIAP and adMare BioInnovations, announced today that it has received funding from NRC IRAP and MITAS for its expansion into the development of ZT-01, a somatostatin receptor 2 antagonist (“SSTR2a”), to Type 2 Diabetes (“T2D”).
Red more here: https://bit.ly/34QRAn6
Read more
AmacaThera, a TIAP Portfolio Company, Closes Seed Financing Round
TORONTO, Oct. 3, 2019 /PRNewswire/ -- AmacaThera Inc. (www.amacathera.ca) is pleased to announce the closing of its US $3.6M seed financing round. A first close of the round was led by Sprout BioVentures/ Viva Biotech with participation from Grey Sky Venture Partners, and the round was recently completed with an investment by Toronto-based Lumira Ventures.
Commenting on the closing of the round, Dr. Molly Shoichet, Ph.D., Co-Founder and Chief Scientific Officer of AmacaThera stated: "We are thrilled to have the Lumira team as part ...
Read more
Zucara Therapeutics Secures Grant from GlycoNet
Toronto & Vancouver, Canada: Zucara Therapeutics Inc., a life sciences company developing the first once-daily therapeutic to prevent hypoglycemia in people with type 1 diabetes and other types of insulin-dependent diabetes, has secured a grant of $69,000 from Canadian Glycomics Network (GlycoNet) to expand and validate the model for its lead drug candidate “ZT-01” from type 1 diabetes (T1D) to type 2 diabetes (T2D). Zucara Therapeutics will match the funding with an additional $85,000 in cash and in-kind contributions, including scientific ...
Read more
2017 Year in Review
MaRS Innovation looks back at the year that was: a summary of the main events of the past 12 months, including creation of LAB150, collaboration with strategic partners and significant investment events into our portfolio companies. For the full report, please follow the link: Year in Review 2017-18
Read more
Zucara Therapeutics Inc. Receives Support from NCR-IRAP
VANCOUVER and TORONTO, Canada — January 8, 2018 - Zucara Therapeutics Inc., a pre-clinical life sciences company advancing a novel long-term therapeutic approach to prevent hypoglycemia in patients with diabetes, has received support of up to $350,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP). In addition, The Centre for Drug Research and Development (CDRD) and MaRS Innovation have contributed follow on funding to the Company’s existing convertible note.
Zucara recently defined its lead drug candidate, ZT-01, and ...
Read more
Ministry of Health and Long Term Care selects BresoTec for Sleep Apnea Test Project
Toronto, Canada, May 16, 2017 – BresoDx®, developed by BresoTec, has been selected by the Ministry of Health and Long-Term Care (MOHLTC) for use in a home-based sleep apnea demonstration project with sleep clinics across Ontario. For the first time in the province,patients and sleep physicians will have the option to diagnose sleep apnea in the home.
Invented at the Toronto Rehabilitation Institute by Dr. Hisham Alshaer, BresoDx® is the world’s first cordless, single-user, home sleep test used to diagnose sleep apnea. BresoDx® aims ...
Read more
Important paper on Type 1 Diabetes and Exercise
New paper published in The Lancet Diabetes & Endocrinology recommends exercise guidelines for type 1 diabetes patients and healthcare providers.
Experts from JDRF, the leading global organization focused on type 1 diabetes (T1D) research, as part of an international team of 21 researchers and clinicians led by York UniversityProfessor Michael Riddell, published first-of-its-kind guidelines to help people with type 1 diabetes exercise safely.
The report, “Exercise management in type 1 diabetes: a consensus statement,” published this week in The Lancet Diabetes & Endocrinology, offers guidelines on ...
Read more